Trevena Granted Key U.S. Method of Use Patent for TRV027

Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 8,796,204, “Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof,” which covers methods of use for TRV027, including a method of treating acute heart failure. The patent is expected to provide coverage for methods of use for TRV027 until at least 2029. Corresponding patent applications are pending in major markets throughout the world. TRV027 is an investigational peptide drug currently being studied in the BLAST-AHF Phase 2b trial for the treatment of acute heart failure (AHF).

“This patent bolsters our intellectual property estate, providing significant coverage for the use of TRV027 in the treatment of acute heart failure,” stated Maxine Gowen, Ph.D., chief executive officer. “Together with granted and pending composition of matter patents worldwide, we believe we are building a comprehensive and enforceable patent portfolio to protect the commercial potential of TRV027.”

Trevena owns all rights to the TRV027 patent portfolio, which includes an issued U.S. composition of matter patent for TRV027 that extends until at least 2031 and additional issued and pending composition of matter patent applications worldwide. Trevena has granted Actavis, Inc. (formerly Forest Laboratories) an exclusive option to license the TRV027 intellectual property portfolio following the completion of the ongoing Phase 2b trial.

About TRV027

TRV027 targets the angiotensin II type 1 receptor, a key driver of AHF, with an innovative “biased ligand” mechanism that simultaneously vasodilates while increasing cardiac performance. This profile has the potential to become an important new therapy for AHF patients.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced three differentiated biased ligand product candidates into the clinic – TRV027 to treat AHF, TRV130 to treat moderate-to-severe acute pain intravenously, and TRV734 to treat moderate-to-severe acute and chronic pain orally. Trevena also is advancing additional product candidates in its portfolio, including a preclinical program focused on central nervous system indications.

Cautionary Note on Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development of its therapeutic candidates, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to the Company’s intellectual property, including the strength, extent of coverage and enforceability of the TRV027 patent portfolio and whether pending patents related to TRV027 will issue; the status, timing, costs, results and interpretation of the Company’s clinical trials; the uncertainties inherent in conducting clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials; expectations for regulatory approvals; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.